TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer

Bowen Yang(Guangzhou University of Chinese Medicine), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Xiujuan Qu(First Hospital of China Medical University), Jin Bai(Xuzhou Medical College), Xiaofang Che(First Hospital of China Medical University), Ye Zhang(First Hospital of China Medical University), Yue Jin(Peking University), Yunpeng Liu(Shenyang Institute of Automation), Yujing Yang(Taiyuan Normal University), Xinye Shao(First Hospital of China Medical University), Ruichuan Shi(Ministry of Education of the People's Republic of China)
International Immunopharmacology
May 6, 2020
10.1016/j.intimp.2020.106532
Cited by 40

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417